No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 13 of the 40 quarters in the window, leaving 27 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 13007.8x · 10Y median 37.4x · 99th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:51.646Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Avalo Therapeutics, Inc. (AVTX) stock was $14.60 as of Oct 5, 2026, 4:00 PM EDT, down 2.60% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +8.9% · 3-year avg -27.4%/yr · 5-year avg -70.0%/yr
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders.
Biotechnology · Wayne, PA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.59
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.83
vs Estimate
$-0.62
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AVTX | $767.46M | $14.60 | -2.60% | +8.91% | -70.04% | -48.70% | N/A |
| 2ATTO | $774.32M | $18.00 | +4.80% | N/A | N/A | N/A | vs AVTX |
| 3DSGN | $775.72M | $12.42 | +0.65% | +102.59% | -3.82% | N/A | vs AVTX |
| 4GERN | $776.24M | $1.21 | +0.83% | -10.32% | -1.87% | -6.18% | vs AVTX |
| 5AHCO | $780.95M | $5.74 | +2.50% | -36.72% | -24.65% | N/A | vs AVTX |
| 6CADL | $749.55M | $10.23 | +0.49% | +83.46% | -1.42% | N/A | vs AVTX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 12 analysts
Average Price Target
$44.08
+201.9% upside
Low
$30.00
Current
$14.60
High
$60.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.81 | $-0.59 | $-0.42 | 6 |
| Quarter ending Dec 2026 | $-0.75 | $-0.55 | $-0.36 | 5 |
| Quarter ending Mar 2027 | $-0.66 | $-0.66 | $-0.66 | 3 |
| Quarter ending Jun 2027 | $-0.73 | $-0.73 | $-0.73 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.71 | $-2.92 | $-2.16 | 8 |
| FY 2027 | $-4.25 | $-2.98 | $-2.35 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.00M | $1.00M | $1.00M | 12 |
| FY 2027 | $1.00M | $1.00M | $1.00M | 12 |
